| Field | Specification |
|---|---|
| Alternative names | Meclofenamate sodium |
| CAS no. | |
| Applications | |
| Source | Endogenous metabolite |
| Molecular weight | |
| Molecular formula | C14H10Cl2NNaO2 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Meclofenamic acid sodium, also known as Meclofenamate sodium, is a non-steroidal anti-inflammatory agent (NSAID). It is a non-selective gap-junction blocker and a highly selective inhibitor of the fat- and obesity-related enzyme (FTO). It has anti-inflammatory and antitumor activities[1][2][3]. It is supplied as a white to off-white solid (C14H10Cl2NNaO2, MW 318.13) at 99.89% purity.
Physical & Chemical Properties
| CAS Number | 6385-02-0 |
|---|---|
| Molecular Formula | C14H10Cl2NNaO2 |
| Molecular Weight | 318.13 g/mol |
| Purity | 99.89% |
| Appearance | Solid |
| Color | White to off-white |
| Structure Classification | Ketones, Aldehydes, Acids |
| SMILES | O=C(O[Na])C1=CC=CC=C1NC2=C(Cl)C=CC(C)=C2Cl |
| Signaling Pathway | Cytoskeleton; Metabolic Enzyme/Protease |
| Initial Source | Endogenous metabolite |
| Solubility | In Vitro: H2O: 100 mg/mL (314.34 mM; Requires sonication) DMSO: 100 mg/mL (314.34 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | 4°C, sealed storage, away from moisture and light. In solvent: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| H2O | 100 mg/mL (314.34 mM) | requires sonication |
| DMSO | 100 mg/mL (314.34 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 1 year) or -20°C (up to 6 months); sealed storage, away from moisture and light; avoid repeated freeze-thaw cycles.
If water is used as the stock solvent, dilute to the working solution and sterilize it through a 0.22 μm filter before use.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.08 mg/mL (6.54 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 2.08 mg/mL (6.54 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 3
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.08 mg/mL (6.54 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
Meclofenamic acid sodium (10, 100, 200 mM, 4 days) suppresses haSMC proliferation and migration[1]. In combination with gefitinib, Meclofenamic acid sodium (4, 6 μM, 48 h) induces caspase-related apoptosis in resistant NSCLC cells[2].
Cell Cycle Analysis[1]
| Cell Line | haSMCs |
|---|---|
| Concentration | 10, 100, 200 mM |
| Incubation Time | 4 days |
| Result | Caused a G2/M-phase block |
Western Blot Analysis[1]
| Cell Line | haSMCs |
|---|---|
| Concentration | 10, 100, 200 mM |
| Incubation Time | 4 days |
| Result | Decreased the expression of p44/42 MAPK. |
In Vivo
In a mouse prostate tumor model, Meclofenamic acid sodium (10 mg/kg/day, injected intraperitoneally for 20 days) displays antitumor activity[2].
| Animal Model | Prostate tumor model in mice[2] |
|---|---|
| Dosage | 10 mg/kg |
| Administration | i.p. |
| Result | Decreased tumor aggression, increased fibrosis, cellular proliferation and vascularity reduction. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Helicobacter pylori CagA elevates FTO to induce gastric cancer progression via a "hit-and-run" paradigm. Cancer Commun (Lond) 2025 May;45(5):608-631. PMID: 39960839
Targeting ATF4-dependent pro-survival autophagy to synergize glutaminolysis inhibition. Theranostics 2021 Jul 25;11(17):8464-8479. PMID: 34373753
Sensor Actuat B-Chem. 2021, 129983.
Anti-resorption role of low-intensity pulsed ultrasound (LIPUS) during large-scale bone reconstruction using porous titanium alloy scaffolds through inhibiting osteoclast differentiation. Biomater Adv 2023 Nov:154:213634. PMID: 37783002
Inhibition of Ca2+-activated chloride channels by the NSAID meclofenamate for anti-diarrhea. Biochem Pharmacol 2026 Apr:246:117710. PMID: 41544862
Pseudorabies virus infection triggers pUL46-mediated phosphorylation of connexin-43 and closure of gap junctions to promote intercellular virus spread. PLoS Pathog 2025 Jan 21;21(1):e1012895. PMID: 39836710
Investigating tunneling nanotubes in ovarian cancer based on two-photon excitation FLIM-FRET. Biomed Opt Express 2021 Mar 9;12(4):1962-1973. PMID: 33996210
Res Sq. 2026 Apr 6.
SSRN. 2025 Jan 27.
